PC
UTHR icon

Plaisance Capital’s United Therapeutics UTHR Stock Holding History

Plaisance Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,535
Closed -$1.17M – 56
2021
Q2 		$1.17M Buy
+6,535
New +$1.24M 0.58% 38

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Plaisance Capital's UTHR Position: Q3 2021 in Review

Plaisance Capital sold out of United Therapeutics (UTHR) in Q3 2021, closing a stake of 6,535 shares — an estimated $1.17M sold.

Plaisance Capital first reported a position in UTHR in Q2 2021 and held it in 1 quarter. The position peaked at $1.17M in Q2 2021. 425 funds tracked by Wall St. Rank hold UTHR as of Q3 2021.

  • Plaisance Capital reported no remaining United Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Plaisance Capital sold 6,535 United Therapeutics shares in Q3 2021, an estimated $1.17M.
  • Plaisance Capital first reported a position in United Therapeutics in Q2 2021 and held it in 1 quarter.
  • Plaisance Capital's United Therapeutics position peaked at $1.17M in Q2 2021.
  • 425 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2021.

Based on Plaisance Capital's 13F filing for Q3 2021, filed 15 Nov 2021.